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Abstract
Background: Fragile X mental retardation 1 (FMR1) premutation can cause develop-
mental problems including autism spectrum disorder (ASD), social anxiety, depres-
sion, and attention deficit hyperactivity disorder (ADHD). These problems fall under 
an umbrella term of Fragile X-associated Neuropsychiatric Disorders (FXAND)  
and is separate from Fragile X-associated Tremor/Ataxia syndrome (FXTAS), a  
neurodegenerative disorder.
Methods/Clinical Case: A 26-year-old Caucasian male with the Fragile X premutation 
who presented with multiple behavior and emotional problems including depression 
and anxiety at 10 years of age. He was evaluated at 13, 18, and 26 years old with age-
appropriate cognitive assessments, psychiatric evaluations, and an MRI of the brain.
Results: The Autism Diagnostic Observation Scale (ADOS) was done at 13 years 
old and showed the patient has autism spectrum disorder (ASD). An evaluation at 
18 years old showed a full-scale IQ of 64. A Kiddie Schedule for Affective Disorders 
and Schizophrenia (K-SADS) performed at 26 years old confirmed the previous im-
pression of social anxiety disorder, agoraphobia disorder, and selective mutism. His 
MRI acquired at 26 years old showed enlarged ventricles, increased frontal subarach-
noid spaces, and hypergyrification.
Conclusion: This is an exemplary case of an FMR1 premutation carrier with sig-
nificant psychiatric and cognitive issues that demonstrates Fragile X-associated 
Neuropsychiatric Disorders (FXAND) as separate from the other well-known  
premutation disorders.
K E Y W O R D S
ASD, FMR1, Fragile X, FXAND, Premutation
1 |  INTRODUCTION
Most individuals with the premutation (55 to 200 CGG 
repeats) in the Fragile X Mental Retardation 1 gene (FMR1, 
OMIM: 309,550) do not have intellectual disability in contrast 
to those with Fragile X Syndrome (FXS) that is caused by the 
full mutation (>200 CGG repeats) in FMR1. However, those 
with the premutation often have other problems including the 
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Fragile X-associated Primary Ovarian Insufficiency (FXPOI) 
before age 40, seen in approximately 20% of female carri-
ers; and the Fragile X-associated Tremor/Ataxia syndrome 
(FXTAS), a neurodegenerative disorder, seen in approxi-
mately 45% of male and 16% of female carriers with the 
premutation after age 50 (Hagerman & Hagerman, 2016). 
The cause of these clinical problems is related to the elevated 
FMR1-mRNA that correlates positively with the increase in 
CGG repeat number in the premutation range. The elevated 
mRNA can be toxic to the cell and is associated with seques-
tration of vital proteins important for neuronal functions, mi-
tochondrial dysfunction, calcium dysregulation, and chronic 
DNA damage repair (Hagerman & Hagerman, 2016).
The premutation can also cause developmental problems 
including social deficits, autism spectrum disorder (ASD), so-
cial anxiety, depression, obsessive compulsive disorder, and 
attention deficit hyperactivity disorder (ADHD) (Chonchaiya 
et al., 2012; Farzin et al., 2006). These problems in addition 
to adult disorders such as chronic fatigue, central pain syn-
drome, migraines, and autoimmune dysfunction fall under 
an umbrella term of Fragile X-associated Neuropsychiatric 
Disorders (FXAND). At least one of these problems oc-
curs in the majority of premutation carriers. Bailey, Raspa, 
Olmsted, and Holiday (2008) found developmental problems 
in about 30% of premutation carriers. These problems are 
related to mRNA toxicity and mitochondrial deficits docu-
mented in children with psychiatric problems and the premu-
tation (Napoli et al., 2018; Song et al., 2016). Premutation 
neurons in culture have higher rates of spikes and they also 
die faster in culture compared to neurons without the premu-
tation (Chen et al., 2009). In addition, GABA deficits have 
been documented in premutation carriers (Conde et al., 2013; 
D'Hulst et al., 2006).
The prevalence of the premutation is approximately 1 in 
200 girls and 1 in 400 boys from newborn screening in the US 
(Tassone et al., 2012). However, in other countries the premu-
tation prevalence may be much higher, such as Colombia, 
Israel and Mallorca (Saldarriaga et al., 2018). The prevalence 
of ASD in premutation males depends on whether they are the 
proband of the family who presents to a developmental center 
or whether they are identified by cascade testing (non-pro-
band) once another family member demonstrates an FMR1 
mutation. In the study by Chonchaiya et al. (2012), of 50 boys 
with the premutation, 68% of the probands had ASD whereas 
28% of the non-probands had ASD and none of the controls 
had ASD. Overall 14% of the boys with the premutation had 
seizures and the presence of seizures was highly correlated 
with ASD (Chonchaiya et al., 2012). Although most of the 
boys in these studies had a normal IQ, a subgroup had mild 
intellectual disability (Chonchaiya et al., 2012).
Here we report a patient with the premutation who has 
been followed clinically from childhood into adulthood to 
demonstrate the trajectory of FXAND symptoms over time.
2 |  CASE PRESENTATION
The patient is a 26-year-old Caucasian male with the 
Fragile X premutation documented via FMR1 (GenBank: 
NG_007529.2) DNA testing who has been diagnosed with 
selective mutism, agoraphobia, and social anxiety disorder 
initially presented at 13 years of age. His CGG repeat size 
was 56, while his FMR1 mRNA was 2.09 (± 0.12) times nor-
mal. He was born full-term after an uneventful pregnancy. 
He did not require resuscitation and did well in the newborn 
period.
Early milestones were appropriate; he sat at 6  months, 
began crawling at 8  months and walking at 13  months. At 
18  months he was saying 4 words but regressed and lost 
his ability to speak. During this time, he received speech 
and language therapy and by the age of 4 he began to speak 
with words again. By 6 years of age he was speaking spon-
taneously in sentences. Initially he was diagnosed with 
dyspraxia. However, he had a history of selective mutism 
particularly when seeing new people or in visiting physicians. 
He has several autistic features including poor eye contact, 
preservations, tantrums, and tactile defensiveness. He is also 
very sound sensitive and chews on his nails excessively. He 
had problems falling asleep at night which has been attributed 
to poor sleeping habits. He was late with toilet training for 
bowel movements until 8 years of age related to his anxiety. 
At 10 years of age he was diagnosed with multiple behavior 
and emotional problems including depression and anxiety, 
which is contributing to his selective mutism. At the time of 
the evaluation at 13 years of age he was started on fluoxetine 
initially, then later citalopram. Eventually he was started on 
sertraline and aripiprazole to improve his mood and anxiety.
His issues with depression, anxiety, and selective mutism 
have continued from childhood into adulthood. Even with 
language and cognitive therapy in conjunction with phar-
macological interventions, his behavior showed minimal 
improvement.
The patient was seen in the MIND Institute, UC Davis 
Medical Center at age 13, 18, and 26 years old. He demon-
strates poor eye contact, some sensory issues, shyness, and 
social anxiety during assessments. The Autism Diagnostic 
Observation Schedule (ADOS) model 3 was done at 13 years 
of age and he received a score of 12, which falls in the autism 
spectrum disorder range.
His Vineland Adaptive Behavior Scales (VABS) score 
at 13  years of age was 74, with communication at 77, 
daily living skills at 81 and socialization at 71. These test 
results confer an adaptive level that is moderately low. He 
was also assessed with the Wechsler Intelligence Scale for 
Children-IV (WISC-IV) at age 13, but because of his op-
positional behavior, testing results were limited. His score 
included two subtests with estimated scores of 53 for per-
ceptual reasoning index (PRI) and 56 for processing speed 
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(PSI). The Wechsler Adult Intelligence Scale (WAIS-IV) was 
performed at 18 years of age showing a full-scale IQ of 64. 
Table 1 summarizes the cognitive assessment results.
The psychiatric evaluation was performed at 26  years 
of age using Kiddie Schedule for Affective Disorders and 
Schizophrenia (K-SADS). The K-SADS confirmed the pre-
vious impression of social anxiety disorder and oppositional 
defiant disorder (subthreshold) in addition to agoraphobia 
disorder and selective mutism. He did not meet the diagnosis 
of Autism. Per mother, the patient is described as having anx-
iety issues in new situations, refusing to cooperate, obstinacy, 
anger issues, and “shutting down” when communicating with 
new people. His anxiety and depressed mood became appar-
ent at around 10 years of age when he began 5th grade in a 
public school. At that time, he had become self-destructive 
and would threaten self-harm. His mood improved after start-
ing a school that catered to children with special needs.
His magnetic resonance imaging (MRI) scans acquired at 
26  years of age show enlarged lateral ventricles, increased 
frontal subarachnoid spaces, disproportionally large hippo-
campal head (bilateral), and hypergyrification (i.e., complex 
cortical folding) (Figure 1). To confirm these observations, Z 
scores of the volumes of the four ventricles and whole brain 
and local gyrification indices (LGI) of 68 cortical areas were 
computed relative to 8 age-matched healthy males (age mean 
25.9 years, SD 1.27 years, range 24–28 years). The volumetric 
data were obtained using Brain GPS (Mori et al., 2016; Tang 
et al., 2013; Wang et al., 2013) followed by machine-learn-
ing based error correction and manual editing (Wang et al., 
2011; Wang, Ngo, Hessl, Hagerman, & Rivera, 2016). LGI 
(Schaer et al., 2008) a measure of gyrification by the ratio 
of total surface area (both hidden within the sulci and ex-
posed on the outer surface of the brain) and exposed surface 
area was quantified using Freesurfer (Dale, Fischl, & Sereno, 
1999; Fischl, Sereno, & Dale, 1999). While the volumes 
of 3rd and 4th ventricles were in the normal range (3rd/4th 
Z  =  –0.91/0.45, 63.7%/65.3%), lateral ventricles were 2.2-
fold enlarged (35.2 ml, Z = 4.09, 0.0043%) and normalized 
whole brain volume was slightly reduced (1.51 L, Z = –1.90, 
94.3%). In addition, he showed significantly increased LGI in 
the areas important for sensorimotor, auditory, language, and 
memory functions (Z = 2.28–5.00, 0.0001%–2.26%).
T A B L E  1  Comparing cognitive assessment from 2006 and 2011
Items 2006 WISC-IV 2011 WAIS-IV
 
Verbal Comprehension N/A 63
Perceptual Reasoning 53 80
Working Memory N/A 65
Processing Speed 56 66
 
Verbal IQ   62
Performance IQ   74
Full Scale IQ   64
Note: Results given in Standard Score (Mean 100, SD 15)
F I G U R E  1  MRI findings. (a, c, e, g) The 26-year-old 
premutation carrier. (b, c, f, h) A 24-year-old male control. (a, b) A 
mid-sagittal slice showing enlarged lateral ventricles and enlarged 
frontal subarachnoid spaces in the carrier (*). (c, d) Disproportionally 
enlarged hippocampal head the length of which is normally 35% of the 
whole length (Hackert et al., 2002).23 Hippocampus, purple; amygdala, 
lime. (e, f) A sagittal slice of the left hemisphere showing more 
complex folding in the carrier at the junction of the frontal, parietal, 
and temporal lobes. (g, h). A lateral view of the reconstructed cortex 
of the left hemisphere showing more complex folding in the pars 
opercularis (p, light brown, LGI = 4.49, Z = 2.38, 1.73%), precentral 
gyrus (r, purple, LGI = 3.79, Z = 4.32, 0.0008%), postcentral gyrus (o, 
red, LGI = 3.81, Z = 3.81, 0.007%), superior temporal gyrus (s, cyan, 
LGI = 4.32, Z = 2.58, 0.49%), and transverse temporal cortex (*, gray, 
LGI = 5.22, Z = 4.00, 0.0032%). Additional areas showing increased 
LGI are: left entorhinal cortex (LGI = 2.54, Z = 3.14, 0.085%), right 
postcentral gyrus (LGI = 3.72, Z = 2.28, p = .023), right superior 
temporal gyrus (LGI = 4.40, Z = 5.00, <0.0001%), and right transverse 
temporal gyrus (LGI = 5.07, Z = 2.66, 0.39%)
(a) (b)
(c) (d)
(e) (f)
(g) (h)
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3 |  DISCUSSION
This case is an example of a premutation carrier with psychi-
atric and cognitive features that can be seen in premutation 
carriers with FXAND. These problems are significantly dif-
ferent from that of FXPOI and FXTAS, the other well-known 
premutation disorders. The patient did not meet the criteria of 
FXTAS because he did not experience tremor/ataxia, nor did 
he have MRI findings found in FXTAS. This presentation is 
unusual for a carrier with only 56 repeats and FMR1 mRNA 
at twice normal levels.
Extensive molecular and mitochondrial studies have al-
ready demonstrated an association with psychiatric disor-
ders and premutation carrier status (Hagerman & Hagerman, 
2016; Song et al., 2016) and that they can occur before neu-
rological problems develop in FXTAS (Hall et al., 2016). The 
most common psychiatric problems seen in young boys with 
the premutation is anxiety (Cordeiro, Abucayan, Hagerman, 
Tassone, & Hessl, 2015). Cordeiro et al. (2015) studied 
35 premutation carriers with the standardized Anxiety 
Disorders Interview Schedule for DSM-IV (ADIS-IV). They 
demonstrated that children and adult fragile X premutation 
carriers are at a higher risk for anxiety disorders, includ-
ing Generalized Anxiety Disorder, Specific Phobia, Social 
Phobia and Obsessive-Compulsive Disorder than the general 
population. This patient presented with psychiatric prob-
lems typical in young premutation carriers, particularly with 
boys having a higher incidence of ASD (Farzin et al., 2006; 
Seritan, A., Ortigas, M., Seritan, S., A. Bourgeois, J., & J. 
Hagerman, R., 2013; Chonchaiya et al., 2012). The rates of 
ASD range from 8% to 73% depending on whether they pre-
sented through cascade testing or as a proband for their fam-
ily (Farzin et al., 2006; Chonchaiya et al., 2012).
The severity of the anxiety disorder has been shown to 
correlate with the presence of ASD in male carriers which is 
consistent with this case study (Cordeiro et al., 2015). Other 
environmental exposures or “background” genetic modifiers 
likely effect the presentation of clinical manifestations in 
carriers (Muzar, Adams, Schneider, Hagerman, & Lozano, 
2014). Chonchaiya et al. (2012) demonstrated that seizures in 
males with the premutation are associated with a higher rate 
of ASD, although our patient did not have clinical seizures.
MRI findings found in this patient were consistent with 
his clinical symptoms and with previous documentation of 
structural changes that can begin in childhood of premutation 
carriers (Wang et al., 2017). The enlarged lateral ventricles 
and increased frontal subarachnoid spaces may be related 
to poor absorption of cerebrospinal fluid that would lead to 
fluid stagnation and sleep problems (Mortazavi et al., 2018; 
Ringstad et al., 2018). Disproportionally large hippocampal 
head and hypergyrification (especially in the primary sen-
sorimotor and auditory cortices) may reflect defective em-
bryonic neurodevelopment that have been shown in knock-in 
mouse model of the premutation and may be associated with 
developmental delay, tactile defensiveness, sound sensitive, 
selective mutism, depression, and anxiety (Cunningham et 
al., 2010).
Molent et al. (2017) demonstrated increased hypergyrifi-
cation and reduce cortical thickness is associated with gen-
eralized anxiety disorder (GAD) in the general population, 
suggesting a neurodevelopmental origin. This study is the first 
report of hypergyrification in a premutation carrier. In animal 
studies, we know that migration of neurons is impacted by the 
premutation (Cunningham et al., 2010). These MRI findings 
may prove useful in tracking GAD in premutation carriers as 
well as the changes in cerebral morphology as these patients 
age and begin to develop other neurological symptoms.
Premutation carriers have shown large phenotypic vari-
ability, ranging from FXTAS (Hagerman & Hagerman, 
2013), psychiatric disorders (Seritan et al., 2013) to neuro-
developmental disorders (Farzin et al., 2006). This underlies 
the importance of identifying FXAND as a separate group of 
premutation disorders which require further treatment studies. 
Patients with this disorder suffer from significant psychiatric 
issues that can occur during childhood before any symptoms 
of FXTAS. It is hypothesized that the RNA toxicity and mi-
tochondrial dysfunction that occurs in FXTAS may also be 
the pathogenesis of FXAND, but further studies are needed. 
It is also possible that this patient has additional genetic mu-
tations that further led to his symptoms, but further studies of 
his genome are necessary to confirm this hypothesis.
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